GLP-1 receptor agonists work by mimicking incretin hormones, enhancing insulin secretion, suppressing appetite, and slowing gastric emptying
States with no obesity GLP-1 coverage: Most remaining states including Texas, Florida, Ohio, New Jersey, and Georgia do not cover GLP-1s for obesity at all
Taken together, evidence suggests that the ENS may mediate gutbrain signaling that regulates metabolic homeostasis
Halminen J, Sattaer N, Rawshani A et al (2022) Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes
If you want more detailed information on GLP-1 diet tips, read our blog post on Diet tips for staying nourished on GLP-1
How does my genetics affect weight rebound when I stop GLP-1